Why Implement Aggregation Alongside Serialization Now?

By Alexander Klemp, Senior Technical Services Project Manager, Sharp Packaging

Regulations put in place by the US Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) have significantly progressed the security of the pharmaceutical supply chain to better protect patients against the threat of counterfeit, falsified, contaminated, or otherwise harmful pharmaceutical products.

As companies worked towards implementing serialization to meet the regulatory deadlines, a regular topic of conversation was whether to introduce aggregation capabilities alongside serialization.

While many companies have been working toward implementing aggregation to support the upcoming DSCSA 2023 deadline, there are still mixed opinions as to whether investing in aggregation will deliver worthwhile returns in regulatory markets where that is not mandated.

In this article, Alexander Klemp, Senior Technical Services Project Manager at Sharp Packaging, describes the business rationale for including aggregation as part of your serialization strategy, beyond the regulatory requirement.